Accessibility StatementSkip Navigation NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=166350&from= ...

TRENDING: See Nvidia's Growing Appetite For Startup Investments Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy. The announcement was highly anticipated given Hims & Hers Health (HIMS) has long discussed its plan to launch a testosterone replacement therapy, or TRT. There will be four options, offered in partnership with privately held Marius Pharmaceuticals. Pricing has yet to be outlined, but will likely run in the ra ...

Core Insights - Dogecoin Cash, Inc. has announced that its subsidiary, PrestoDoctor, will accept cryptocurrency payments for medical cannabis evaluations, including Dogecoin and other digital assets, as part of a strategy to embrace decentralized technologies [1][3] - The integration of cryptocurrency payments aims to enhance accessibility for a tech-savvy patient base while maintaining traditional payment methods for broader patient choice [3][4] - The move is positioned as a way to enhance patient privacy and adapt to the evolving landscape of healthcare and digital finance [4] Cryptocurrency Acceptance - The cryptocurrencies accepted by PrestoDoctor include Bitcoin (BTC), Ethereum (ETH), USD Coin (USDC), Tron (TRX), Tether (USDT), Binance Coin (BNB), Dogecoin (DOGE), Litecoin (LTC), Monero (XMR), Polygon (MATIC), Bitcoin Cash (BCH), Shiba Inu (SHIB), Solana (SOL), and DAI [6] Company Overview - Dogecoin Cash, Inc. is focused on advancing blockchain technology and its applications in healthcare, finance, and consumer services, with PrestoDoctor providing telemedicine solutions for medical cannabis evaluations across multiple U.S. states [4][5]

Core Insights - Dogecoin Cash, Inc. has announced that its subsidiary, PrestoDoctor, will accept cryptocurrency payments for medical cannabis evaluations, including Dogecoin and other digital assets, as part of a strategy to embrace decentralized technologies [1][3] - The integration of cryptocurrency payments aims to enhance accessibility for a tech-savvy patient base while maintaining traditional payment options [3][4] - The move is positioned as a way to offer enhanced privacy and stay ahead in the evolving landscape of healthcare and digital finance [4] Cryptocurrency Acceptance - The cryptocurrencies accepted by PrestoDoctor include Bitcoin (BTC), Ethereum (ETH), USD Coin (USDC), Tron (TRX), Tether (USDT), Binance Coin (BNB), Dogecoin (DOGE), Litecoin (LTC), Monero (XMR), Polygon (MATIC), Bitcoin Cash (BCH), Shiba Inu (SHIB), Solana (SOL), and DAI [6] Company Overview - Dogecoin Cash, Inc. is focused on advancing blockchain technology and its applications in healthcare, finance, and consumer services, with PrestoDoctor providing telemedicine solutions for medical cannabis evaluations across multiple U.S. states [4][5]

Core Viewpoint - The article discusses the declining prospects of Teladoc Health and Sarepta Therapeutics, suggesting that despite their stock price drops, they do not present attractive investment opportunities at this time. Teladoc Health - Teladoc's revenue declined by 2% year over year to $631.9 million in the second quarter, indicating slower growth compared to previous periods [3] - The company reported a net loss per share of $0.19 for the second quarter, an improvement from a loss of $4.92 per share in the same quarter last year, but still reflects ongoing unprofitability [4] - Teladoc has faced goodwill impairment charges related to its BetterHelp segment, contributing to its negative financial performance [6] - A significant portion of Teladoc's expenses is allocated to marketing, which has not resulted in desired revenue growth [7] - The company is expanding its ecosystem and international presence, with a reported 11% year-over-year increase in enrollment to 102.4 million members, but faces uncertainty due to ongoing losses and competition [8] Sarepta Therapeutics - Sarepta's shares have declined by 85% this year, primarily due to two patient deaths linked to liver toxicity from its gene therapy Elevidys for Duchenne muscular dystrophy [9] - In the first quarter, Sarepta generated $744.9 million in revenue, an 80% increase year over year, with Elevidys accounting for $375 million of that total [11] - The second quarter saw revenue drop to $362.9 million, a 51.2% sequential decline, with Elevidys sales falling 67.5% to $121.7 million, indicating reduced demand [12] - The company is working with the FDA to resume shipping Elevidys and has implemented cost-cutting measures, including layoffs, to manage its financial situation [13] - Despite efforts to stabilize, significant uncertainties remain, particularly following another patient death in a clinical trial for a different therapy, making the stock unattractive at its current price [14][15]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's competitive position and customer acquisition costs [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that LifeMD's defendants made materially false and misleading statements about the company's competitive position and financial guidance, particularly regarding customer acquisition costs in the RexMD segment and the sale of obesity treatment drugs [5]. - Investors who purchased LifeMD securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 27, 2025, to represent other class members in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The complaint against LifeMD alleges that the company and its executives violated federal securities laws by making misleading statements and failing to disclose critical information regarding their competitive position and customer acquisition costs [2]. Financial Performance - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from the previous guidance of $268 to $275 million [3]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [3]. Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4]. - The law firm Faruqi & Faruqi encourages individuals with information regarding LifeMD's conduct to come forward, including whistleblowers and former employees [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against LifeMD, Inc. following disappointing Q2 2025 financial results and a reduced outlook, which was raised just three months prior [1][5]. Group 1: Lawsuit Details - The lawsuit seeks to represent investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for October 27, 2025 [3]. - The litigation focuses on LifeMD's statements made on May 6, 2025, when the company reported its Q1 2025 financial results and raised its full-year 2025 revenue and adjusted EBITDA guidance [3]. Group 2: Financial Performance and Guidance - LifeMD raised its guidance in May 2025, citing the creation of a competitive moat in virtual obesity care and strong performance from its RexMD brand [4]. - The company later reported Q2 2025 results that missed consensus estimates, reducing revenue guidance by approximately 6.7% to 7.3% and slashing adjusted EBITDA guidance by about 12% to 13% [5][6]. - The disappointing results were attributed to higher-than-anticipated refund rates and elevated customer acquisition costs in the competitive ED market [6]. Group 3: Investigation and Claims - Hagens Berman, a national shareholders rights firm, has opened an investigation into whether LifeMD violated securities laws [2][7]. - The investigation is focused on whether LifeMD recklessly guided on May 6, 2025, while facing challenges in its weight management and RexMD segments [7]. - The complaint alleges that LifeMD made false and misleading statements and failed to disclose crucial information while insiders sold significant amounts of their shares [4].

Core Viewpoint - Earth Science Tech, Inc. has approved a significant enhancement and a two-year extension of its common stock repurchase program, increasing total authorization to $10 million, which will now run through December 31, 2027 [1][2][3] Repurchase Program Details - The company has already deployed over $1.8 million to repurchase 20,834,214 shares since the program's inception on January 29, 2024, reflecting a commitment to enhancing shareholder value [2][4][8] - The remaining authorization for the repurchase program is $8,169,104.50, with the new expiration date set for December 31, 2027 [8] Company Overview - Earth Science Tech, Inc. operates as a strategic holding company focused on acquiring and scaling high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through its subsidiaries [5][6] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [5][7][9]

Core Points - Earth Science Tech, Inc. has announced a reduction in its authorized shares of common stock from 350 million to 300 million, reflecting the Board's confidence in the company's trajectory and commitment to long-term shareholder value [1][2][3] - The current outstanding share count is approximately 294.3 million, leading the Board to determine that the previous authorization level was unnecessary [3] Company Overview - Earth Science Tech, Inc. operates as a strategic holding company focused on acquiring and scaling high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through its subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][6][10] - RxCompoundStore.com is a licensed compounding pharmacy operating in multiple states and is actively pursuing licensure in the remaining U.S. states [5] - Peaks Curative is a telemedicine platform that offers consultations for compounded medications and is expanding its services nationwide [7] - Avenvi is involved in real estate development and manages the company's ongoing $5 million share repurchase program [10]